Product Name: Herpes Simplex Virus 2 (HSV 2) IgM - ELISA
# of Samples: 1 x 96 Assays
Intended Use: The HSV 2 IgM recombinant ELISA allows the detection of HSV 2 infection in presence of antibodies to HSV 1 in human serum or plasma (citrate).
Introduction: Herpes simplex is an enveloped DNA virus (150-200 nm in diameter) belonging to the alpha-herpesviridae. Based on antigenic, biochemical and biologically differences it can be divided into two serotypes, HSV-1 and HSV-2. Man is the only known natural host and source of the virus. HSV type 1 typically causes oral herpes, while HSV type 2 typically affects the genital area. Most of the time, HSV-1 and HSV-2 are inactive, or ?silent?, and cause no symptoms, but some infected people have ?outbreaks? of blisters and ulcers. Once infected with HSV, people remain infected for life. Herpes simplex viruses are amongst the most common infectious agents of man, and either HSV type appears to be capable of infecting similar body sites. A high percentage of the adult population
is seropositive (appr. 90% HSV-1, in dependence on the socio-economic status 10-30% HSV-2). Primary HSV-1 infection usually occurs in early childhood (6 to 18 months of age). HSV-2 usually produces mild symptoms, and most people have no recognized symptoms. Persons at risk are children with inherited T-cell deficiencies and patients who are immunosuppressed because of infection (e.g. HIV), transplantation, or cancer therapy.
HSV-2 can cause potentially fatal infections in infants if the mother is shedding virus at the time of delivery. - HSV-2 may play a major role in the heterosexual spread of HIV: herpes can make people more susceptible to HIV infection, and HIV-infected individuals more infectious.
The presence of virus resp. infection may be identified by
Microscopy: CPE, IF
Serology: Detection of antibodies by ELISA
Principles of the assay: The qualitative immunoenzymatic determination of IgM-class antibodies against HSV Type 2 is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique.
Microtiter strip wells are precoated with HSV Type 2 recombinant antigens to bind corresponding antibodies of the specimen. After washing the wells to remove all unbound sample material horseradish peroxidase (HRP) labelled anti-human IgM conjugate is added. This conjugate binds to the captured HSV Type 2 specific antibodies. The immune complex formed by the bound conjugate is visualized by adding Tetramethylbenzidine (TMB) substrate which gives a blue reaction product. The intensity of this product is proportional to the amount of HSV Type 2 specific IgM antibodies in the specimen. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint colour. Absorbance at 450 nm is read using an ELISA microwell plate reader.
Storage and Stability: The reagents are stable up to the expiry date stated on the label when stored at 2...8 °C.
References: Corey, L.; P.G. Spear: Infections with herpes simplex viruses. N. Engl. J. Med. 314 (1986) 686-691Dörries, R., R. Kaiser, H. Imrich et al.: Neuere Aspekte zur Diagnose zentralnervöser Virusinfektionen. Lab. Med. 15 (1991) 99-102Felgenhauer, K.: Diagnostische Bedeutung der lokal synthetisierten spezifischen Antikörper des Liquor cerebrospinalis. Lab. Med. 15 (1991) 208 Kaufmann, H.E.;F. Martola and C. Dohlman: The use of 5-iodo-2?-deoxy-uridine (IDU) in the treatment of herpes simplex keratitis. Arch. Ophthal. N. Y. 68 (1962) 235-239Spaar, F.-W.: Die menschliche Herpes simplex Enzephaltits und Meningitis. Eine klinisch-neurologische Untersuchung. G. Fischer Verlag, Stuttgart, New York (1976)